NCT00039195View on ClinicalTrials.gov

Chemotherapy and Rituximab With or Without Total-Body Irradiation and Peripheral Stem Cell Transplant in Treating Patients With Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions
Lymphoma
Interventions
BIOLOGICAL

filgrastim

BIOLOGICAL

rituximab

DRUG

carboplatin

DRUG

cyclophosphamide

DRUG

doxorubicin hydrochloride

DRUG

etoposide

DRUG

ifosfamide

DRUG

prednisone

DRUG

vincristine sulfate

PROCEDURE

peripheral blood stem cell transplantation

RADIATION

radiation therapy

Trial Locations (1)

10065

Memorial Sloan-Kettering Cancer Center, New York

Sponsors
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Genentech, Inc.

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00039195 - Chemotherapy and Rituximab With or Without Total-Body Irradiation and Peripheral Stem Cell Transplant in Treating Patients With Lymphoma | Biotech Hunter | Biotech Hunter